



**BioLight Life Sciences Ltd.
(The “Company”)**

August 24, 2023

**Re: Tarsier Pharma (Company’s affiliate) announces results achieved from its
Phase III Clinical Trial in the USA**

Further to the Company’s announcement of September 2021 in reference to the beginning of Tarsier Pharma’s phase III clinical trial (Tarsier Pharma) which examines the efficacy and safety of the TRS01, Tarsier’s flagship product in patients with anterior, non-infectious uveitis, and specifically in uveitis- glaucoma patients (The Experiment), the Company is proud to announce that Tarsier Pharma has received the final results of the experiment.

The experiment revealed that its TRS01 product, a formulation of eye drops with new anti-inflammatory molecules with a high mechanism of action, showed anti-inflammatory activity in uveitis patients without significant side effects. The active control group of steroid treatments was found to be more effective in reducing inflammation at the end of 4 weeks, however, the TRS01 did not raise eye pressure as much as steroids, which was the primary goal of the experiment (primary endpoint). Eye pain, inflammation, and pressure in the eye were measured. Even though TRS01 didn't completely get rid of inflammation as well as steroids did, it still had positive effects revealing that TRS01 seems to help with inflammation without raising intraocular pressure which can lead to glaucoma. TRS01 also seems to be safe for patients with uveitis and especially for uveitis-glaucoma patients.

The Company has also been informed that Tarsier Pharma is preparing for a meeting with the FDA in order to determine the optimal way to advance the approval of its TRS01 product in the United States.

The study enrolled a total of 142 patients in 30 clinical sites across the USA and Europe.

Forward-Looking Statement

The information and details contained in this report regarding the phase III clinical trial for the TRS01 product as well as forecasts, deadlines, estimates and/or plans of the company and/or Tarsier Pharma in connection with the aforementioned, are "forward-looking information" as defined in the Securities Law Value, 1968-1968 which involves high uncertainty, and is based, among other things, on third parties and many variables over which the company and/or Tarsier Pharma do not necessarily have control, and therefore it is possible that the aforementioned information and estimates, in practice, will not be realized and/or will not be fully realized and/or will materialize in a way that is fundamentally different from what was initially estimated or observed.

About BioLight

BioLight Life Sciences Ltd. is a leading company investing in companies and managing projects in the field of eye diseases and ocular treatments. BioLight’s portfolio companies engage in advanced medical devices, medication, diagnostics and digital medicine designed to improve the efficacy and safety of treatments of eye diseases exemplifying the enormous potential of Israeli innovation in these fields.